ADAP
Adaptimmune Therapeutics
ADAP
ADAP
Delisted
ADAP was delisted on the 27th of October, 2025.
80 hedge funds and large institutions have $397M invested in Adaptimmune Therapeutics in 2018 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 27 increasing their positions, 24 reducing their positions, and 27 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less ownership
Funds ownership: →
less funds holding
Funds holding: →
48% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 27
50% less funds holding in top 10
Funds holding in top 10: 6 → 3 (-3)
55% less capital invested
Capital invested by funds: $888M → $397M (-$491M)
Holders
80
Holding in Top 10
3
Calls
$2.25M
Puts
$136K
Top Buyers
| 1 | +$39M | |
| 2 | +$3.93M | |
| 3 | +$3.71M | |
| 4 |
JPMorgan Chase & Co
New York
|
+$1.65M |
| 5 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$1.62M |
Top Sellers
| 1 | -$9.47M | |
| 2 | -$7.67M | |
| 3 | -$5.17M | |
| 4 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
-$4.85M |
| 5 |
QF
QVT Financial
New York
|
-$4.85M |